TriSalus Life Sciences (NASDAQ:TLSI) Receives “Buy” Rating from Canaccord Genuity Group

Canaccord Genuity Group restated their buy rating on shares of TriSalus Life Sciences (NASDAQ:TLSI) in a research note published on Thursday morning, Benzinga reports. They currently have a $12.00 price objective on the stock.

A number of other equities research analysts also recently issued reports on the company. Canaccord Genuity Group initiated coverage on TriSalus Life Sciences in a research report on Thursday, May 30th. They set a buy rating and a $12.00 price objective on the stock. Jonestrading started coverage on TriSalus Life Sciences in a research report on Friday, May 10th. They issued a buy rating and a $16.00 price target for the company.

TriSalus Life Sciences Trading Up 1.9 %

NASDAQ TLSI opened at $5.76 on Thursday. The stock has a 50 day moving average price of $8.18 and a 200-day moving average price of $8.76. TriSalus Life Sciences has a one year low of $3.32 and a one year high of $16.24.

TriSalus Life Sciences (NASDAQ:TLSI) last posted its earnings results on Wednesday, May 15th. The company reported ($0.54) earnings per share for the quarter. The firm had revenue of $6.46 million for the quarter.

Institutional Investors Weigh In On TriSalus Life Sciences

A hedge fund recently bought a new stake in TriSalus Life Sciences stock. Tyche Wealth Partners LLC purchased a new stake in shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 26,664 shares of the company’s stock, valued at approximately $225,000. Tyche Wealth Partners LLC owned approximately 0.10% of TriSalus Life Sciences as of its most recent filing with the Securities & Exchange Commission. 2.58% of the stock is currently owned by institutional investors.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.